Retatrutide
An investigational peptide that acts on three hormone receptors (GIP, GLP-1 and glucagon).
Quick Answer
An investigational peptide that acts on three hormone receptors (GIP, GLP-1 and glucagon). It was developed by Eli Lilly and has been studied in clinical trials.
Placeholder
This is a short outline. The full profile is written only once its sources have been checked, and it will then link each line below to a study summary.
Basics
| Name | Retatrutide |
|---|---|
| Type | Investigational peptide |
| Regulatory Status | To be confirmed from a current source |
Key Areas of Research
Published research on Retatrutide has looked at the following areas. The label shows the type of study.
- Human study Body weight and other metabolic measures in people with overweight or obesity, reported in clinical trials.
- Human study Blood sugar measures in people with type 2 diabetes, reported in clinical trials.
- Human study Liver fat in people with fatty liver disease, reported in trial sub-studies.
- Animal study How activating the three receptors together affects energy balance in animal models.
What Is Not Known
Trials were still running when this outline was written, so the long-term picture is incomplete. The regulatory status needs to be confirmed from a current source before this profile is finished.
For Research Use Only
This page reports what published studies and researchers have found. It is information, not advice.